Original paper

Cancer Causes & Control

, Volume 17, Issue 9, pp 1155-1162

First online:

Oral contraceptive use and risk of breast carcinoma in situ (United States)

  • Jasmeet K. GillAffiliated withEtiology Program, Cancer Research Center of Hawaii, University of Hawaii
  • , Michael F. PressAffiliated withDepartment of Pathology and Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California
  • , Alpa V. PatelAffiliated withDepartment of Epidemiology and Surveillance Research, American Cancer Society
  • , Leslie BernsteinAffiliated withDepartment of Preventive Medicine and Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



Our study assesses the impact of oral contraceptive use on breast carcinoma in-situ (BCIS) risk.


We conducted a population based case–control study of incident BCIS among black and white women ages 35–64 years residing in Los Angeles County. Case patients (n = 567) were newly diagnosed with BCIS and control participants (n = 614) were identified by random digit dialing between 1 March 1995 and 31 May 1998. All subjects were required to have had a mammogram in the 2 years before case diagnosis or control recruitment. Data were collected during in-person interviews. Multivariable logistic regression analyses provide estimates of odds ratios (ORs) and 95% confidence intervals (95% CIs).


Oral contraceptive use was not associated with risk of BCIS (OR = 1.04, 95% CI (0.76–1.42)). Risk did not increase with longer periods of use. No associations with BCIS risk were observed for oral contraceptive use before first term pregnancy, age at first oral contraceptive use, or for time since last use. Risk was not modified by estrogen dose, age, race, or parity.


Our results are consistent with recent results on invasive breast cancer reported for the Women’s Contraceptive and Reproductive Experiences Study and show no association between oral contraceptive use and risk of BCIS.


Breast carcinoma in situ Oral contraceptives Risk Case–control